tiprankstipranks
Trending News
More News >
Elicio Therapeutics, Inc (ELTX)
:ELTX
Advertisement

Elicio Therapeutics (ELTX) Stock Statistics & Valuation Metrics

Compare
209 Followers

Total Valuation

Elicio Therapeutics has a market cap or net worth of $173.19M. The enterprise value is $116.79M.
Market Cap$173.19M
Enterprise Value$116.79M

Share Statistics

Elicio Therapeutics has 16,338,284 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,338,284
Owned by Insiders34.32%
Owned by Institutions4.96%

Financial Efficiency

Elicio Therapeutics’s return on equity (ROE) is 4.59 and return on invested capital (ROIC) is -256.24%.
Return on Equity (ROE)4.59
Return on Assets (ROA)-1.84
Return on Invested Capital (ROIC)-256.24%
Return on Capital Employed (ROCE)-2.70
Revenue Per Employee0.00
Profits Per Employee-1.62M
Employee Count32
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Elicio Therapeutics is ―. Elicio Therapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value-5.50
Price to FCF
Price to Operating Cash Flow-4.42
PEG Ratio

Income Statement

In the last 12 months, Elicio Therapeutics had revenue of 0.00 and earned -51.90M in profits. Earnings per share was -4.25.
Revenue0.00
Gross Profit-1.18M
Operating Income-44.99M
Pretax Income-51.90M
Net Income-51.90M
EBITDA-50.27M
Earnings Per Share (EPS)-4.25

Cash Flow

In the last 12 months, operating cash flow was -35.09M and capital expenditures -45.00K, giving a free cash flow of -35.13M billion.
Operating Cash Flow-35.09M
Free Cash Flow-35.13M
Free Cash Flow per Share-2.15

Dividends & Yields

Elicio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.53
52-Week Price Change166.33%
50-Day Moving Average9.24
200-Day Moving Average7.13
Relative Strength Index (RSI)55.09
Average Volume (3m)106.10K

Important Dates

Elicio Therapeutics upcoming earnings date is Nov 6, 2025, After Close (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date

Financial Position

Elicio Therapeutics as a current ratio of 1.80, with Debt / Equity ratio of 812.54%
Current Ratio1.80
Quick Ratio1.80
Debt to Market Cap0.34
Net Debt to EBITDA-0.17
Interest Coverage Ratio-98.87

Taxes

In the past 12 months, Elicio Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Elicio Therapeutics EV to EBITDA ratio is -1.41, with an EV/FCF ratio of -1.90.
EV to Sales0.00
EV to EBITDA-1.41
EV to Free Cash Flow-1.90
EV to Operating Cash Flow-1.91

Balance Sheet

Elicio Therapeutics has $22.09M in cash and marketable securities with $14.90M in debt, giving a net cash position of -$7.19M billion.
Cash & Marketable Securities$22.09M
Total Debt$14.90M
Net Cash-$7.19M
Net Cash Per Share-$0.44
Tangible Book Value Per Share-$0.93

Margins

Gross margin is -22.81%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-22.81%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Elicio Therapeutics is $12.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$12.50
Price Target Upside17.92% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast
EPS Growth Forecast-4.60%

Scores

Smart Score4
AI Score30.25
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis